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DETECTION OF EPIGENOMIC NETWORK COMMUNITY
ONCOMARKERS
By Thomas E. Bartlett∗,†,§, and Alexey Zaikin‡,§
University College London§
In this paper we propose network methodology to infer prognostic
cancer biomarkers based on the epigenetic pattern DNA methylation.
Epigenetic processes such as DNA methylation reflect environmen-
tal risk factors, and are increasingly recognised for their fundamental
role in diseases such as cancer. DNA methylation is a gene-regulatory
pattern, and hence provides a means by which to assess genomic reg-
ulatory interactions. Network models are a natural way to represent
and analyse groups of such interactions. The utility of network mod-
els also increases as the quantity of data and number of variables
increase, making them increasingly relevant to large-scale genomic
studies. We propose methodology to infer prognostic genomic net-
works from a DNA methylation-based measure of genomic interaction
and association. We then show how to identify prognostic biomarkers
from such networks, which we term ‘network community oncomark-
ers’. We illustrate the power of our proposed methodology in the
context of a large publicly available breast cancer dataset.
1. Introduction. Complex systems which can be modelled as networks
are ubiquitous. Well-known examples include social/communication net-
works (Beguerisse-Dı´az et al., 2014) and economic networks (Saavedra et al.,
2014), as well as many others in the biological sciences such as ecological
networks (Nandi, Sumana and Bhattacharya, 2014), gene networks (Wei
and Pan, 2010; Li and Wang, 2014), protein networks (Mardia, 2013; Tran
and Kwon, 2013), and metabolic networks (Reznik, Watson and Chaudhary,
2013). Over the past few years in cell biology, much focus has shifted from
investigation of individual genes, to pathways of genes, to gene networks.
The interest in novel methodology for network analysis in cell biology fol-
lows from the recognition that examining the way genes work in groups often
∗thomas.bartlett.10@ucl.ac.uk
†TB acknowledges funding from EPSRC grant no. EP/M507970/1 and previous support
from EPSRC and MRC via UCL CoMPLEX.
‡AZ acknowledges support from the Deanship of Scientifc Research (DSR), King Ab-
dulaziz University (KAU), Jeddah, under grant No. (86-130-35-RG) and from the Russian
Foundation for Basic Research (14-02-01202,13-02-00918).
Keywords and phrases: Computational biology, stochastic networks, community detec-
tion, epigenomics.
1
ar
X
iv
:1
50
6.
05
24
4v
3 
 [s
tat
.A
P]
  1
 A
ug
 20
16
2 T.E. BARTLETT ET AL
yields more accurate inference of biological processes.
The problem of finding community structure in networks has been studied
for many years. Important applications of this problem include identifying
groups of friends or co-workers in social networks, as well as identifying
functional subnetwork modules in biological networks (Girvan and New-
man, 2002). In the biological setting, genes can be viewed as acting together
as part of ‘subnetwork modules’, which are functional units with specific
biological roles (Shen-Orr et al., 2002). Indeed, it has been demonstrated
recently that such modularity is a natural and even inevitable result of
evolutionary pressures (Clune, Mouret and Lipson, 2013). This is because
modularity minimises network connectivity cost whilst maximising perfor-
mance, and thus it represents the most parsimonious and efficient type of
network structure for biological networks such as these. Furthermore, consid-
ering groups of genes defined together as subgraphs can lead to big increases
in statistical power, aiding discovery of biological phenomena (Jacob et al.,
2012; Li and Li, 2010; Peng et al., 2010). Therefore, it is relevant to both the
biological and statistical modelling to consider the group behaviour of genes
in this way. Hence, this viewpoint of modular genomic network structure is
fundamental to the methodology we propose here.
Epigenetic patterns are gene-regulatory patterns, meaning that they influ-
ence the activity of particular genes, among other phenomena (Jones, 2012).
Epigenetic information can be modulated during the lifetime of an organ-
ism by environmental cues (Feinberg, Ohlsson and Henikoff, 2006; Cooney,
2007; Christensen et al., 2009). As such, epigenetics can be considered to
be an interface between the genome and the environment, and consequently
also a conduit for environmental risk factors. Alterations in the epigenetic
pattern DNA methylation are among the earliest changes in human carcino-
genesis (Feinberg, Ohlsson and Henikoff, 2006), and hence DNA methylation
patterns are expected to yield important prognostic information useful for
biomarker development. DNA methylation patterns are thought promising
for biomarker development in a wide variety of physiological systems and
organs (Verschuur-Maes, de Bruin and van Diest, 2012; Van Hoesel et al.,
2013; Fleischer et al., 2014; Kishida et al., 2012; Gao et al., 2013; Kang
et al., 2001, 2003; Bhagat et al., 2012; Yamamoto et al., 2012; Luo et al.,
2014; Navarro et al., 2012; Maekawa et al., 2013).
It is well established that DNA methylation plays an important role in
gene regulation, and hence DNA methylation patterns often reflect gene reg-
ulatory behaviour (Jones, 2012). Changes in DNA methylation are highly
stochastic. The timescale over which these changes take place is much faster
than DNA mutations can arise, but much slower than the transient and
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periodically varying activity of individual genes, and this timescale is ideal
for biomarker development. DNA methylation data are extremely noisy;
however, statistics which summarise DNA methylation patterns at the gene
level have been shown to have much utility as analytical tools (Bartlett
et al., 2013). It has been shown previously that DNA methylation can serve
as a surrogate measure of genomic-regulatory action (Brocks et al., 2014).
Hence, DNA methylation measurements are a natural basis from which to
construct genomic regulatory and related networks. As a cancer progresses,
its signalling and control networks are rearranged (‘rewired’), leading to ge-
nomic changes which are advantageous for the cancer (Baraba´si and Oltvai,
2004). Previous research has found that patient survival outcome in breast
cancer can be predicted well by network models of this rewiring, based on
gene expression data (Taylor et al., 2009). Hence, network models based on
DNA methylation measurements are a very promising basis for the develop-
ment of prognostic biomarkers.
Statistical network models are a parsimonious way to represent and anal-
yse large numbers of variables and samples. They are efficient analytical
tools appropriate for the very large datasets which are produced by the lat-
est technologies in cell biology. When carrying out modelling of this type,
it is important to balance statistical fidelity with computational efficiency.
The ‘stochastic blockmodel’ (SBM) (Holland, Laskey and Leinhardt, 1983;
Bickel and Chen, 2009) is an efficient network model which has been widely
studied and is well understood, and hence it is a good basis for our pro-
posed methodology. Under the SBM, there is a greater probability of ob-
serving an edge (or interaction) between a pair of nodes if they are in the
same block, or community. The Newman-Girvan modularity (Newman and
Girvan, 2004) quantifies the extent to which network edges are observed
between community members, for a particular assignment of nodes to com-
munities, compared to the expected number of edges between community
members if there were no community structure present. It can be shown that,
under certain conditions, fitting the stochastic blockmodel is equivalent to
maximising the Newman-Girvan modularity over a network, and that these
are both equivalent to spectral clustering (Riolo and Newman, 2012; Bickel
and Chen, 2009). We use spectral clustering as an efficient computational
algorithm for fitting the SBM.
It has also been shown recently that, under reasonable assumptions, the
SBM can be used to represent any network as a ‘network histogram’, what-
ever the generating mechanism of that network. Further, the network his-
togram provides a heuristic method to estimate the optimum number of
blocks, or clusters, which a valid blockmodel representation of the net-
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work may contain. This is important and useful, because it means that
the blockmodel can be used to identify an unknown number of communi-
ties, or functional subnetwork modules, in a biological network. Genomic
networks are typically scale-free, which means that they exhibit a power-
law degree distribution (Wagner, 2002). Further, they are thought to be
hierarchical (Baraba´si and Oltvai, 2004; Palla, Lova´sz and Vicsek, 2010),
displaying multi-scale properties. This means that different functional or-
ganisation is visible at different granularities, or scales. We use the network
histogram method (Olhede and Wolfe, 2014) to estimate the optimal granu-
larity at which to identify communities, or functional subnetwork modules,
in our prognostic networks by fitting the SBM.
The main contribution of this work is to propose a well-integrated, and
well-validated, statistical methodology for detecting biomarkers from the bi-
ological viewpoint of modular genomic network structure, using DNA-based
measurements of genomic regulatory patterns. To do this, we show how to
integrate our previously proposed DNA methylation-based measure of in-
teraction or association between pairs of genes, the ‘DNA methylation net-
work interaction measure’ (Bartlett, Olhede and Zaikin, 2014), into a multi-
stage pipeline to construct prognostic network community-based biomarkers.
This leads to our novel and generally applicable statistical methodology; we
present the multiple stages of this methodology sequentially here, and thus
this paper is organised as follows. In Section 2, we outline our previously
proposed DNA methylation network interaction measure (Bartlett, Olhede
and Zaikin, 2014), and we show how to use this measure to infer prog-
nostic genomic networks. An edge between a pair of genes/nodes in these
networks indicates that the strength of interaction or association between
those genes is associated with disease progression. Also, in Section 2, we
show how to identify prognostic biomarkers from such networks, using com-
munity detection to identify subnetwork modules within the network. These
communities are groups of nodes/genes among which there is a high density
of prognostic interactive or associative behaviour, and we term them ‘net-
work community oncomarkers’. In Section 3, we demonstrate the utility of
our proposed methodology in the context of a large, publicly available breast
cancer dataset. To do so, we use each network community oncomarker to
calculate a one-number prognostic score for each patient, and we use these
scores to classify patients one by one into prognostic groups. Also in Section
3, we show that among the genes of the network community oncomark-
ers, the DNA methylation network interaction measure is associated with
co-regulatory behaviour as measured by gene expression, justifying these
findings in terms of biological function.
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2. Proposed methodology. An overview of our proposed methodol-
ogy appears in Figure 1, following which component parts of this method-
ology are described in detail.
(1) Calculate the DNAm network interaction measure 
for each pair of genes, and for each patient
(2) Calculate a Wald statistic (adjusted for clinical covariates) as a measure
of prognostic ability for each pair of genes, across all patients
(3) Infer the prognostic network, by fitting a mixture model to identify 
significantly non-zero Wald statistics, defining these 
prognostic interactions as network edges
(4) Detect network community oncomarkers as groups of genes among 
      which there is a high density of prognostic interactions / network edges 
(5) Summarise the DNA methylation network interaction measures over
           the prognostic interactions / network edges of each network community 
oncomarker, to give a one-number prognostic score for each 
patient, and for each network community oncomarker
Fig 1: Overview of methods.
We note that, in principle, each of the steps illustrated in Figure 1 could be
replaced with alternative choices of methodology.
2.1. DNA Methylation Network Interaction Measure. DNA methylation
is a chemical modification to DNA which may occur at numerous locations
within a gene: the pattern of these modifications within a gene forms a ‘DNA
methylation profile’. Using canonical correlation analysis (CCA) (Hotelling,
1936) we previously proposed a statistic (Bartlett, Olhede and Zaikin, 2014)
which measures the strength of interaction or association between a pair of
genes (network nodes) in a single sample/patient, based on DNA methyla-
tion profiles (Figure 2). This statistic quantifies the extent to which the DNA
methylation profiles of a pair of genes explain each other. It is based only
on measurements of the DNA methylation profiles of that pair of genes, and
it acts as a surrogate for a measure of the extent to which this pair of genes
behave interactively or associatively. Such behaviour may include transcrip-
tional regulation or co-regulation, or other types of biochemical interaction,
influencing gene expression levels, isoforms and the presence of alternatively
spliced gene products, among other phenomena (Jones, 2012). The details
of this DNA methylation network interaction measure are as follows.
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The DNA methylation network interaction measure is defined by analogy
to CCA. CCA aims to discover linear combinations of variables of one type,
and linear combinations of variables of another type, so that these combina-
tions best explain each other. In this context, a particular way of combining
(by scaling and adding) the deviations from the mean methylation profile
at a number of locations within one gene might be particularly effective at
explaining a particular combination of (again, by scaling and adding) the
deviations from the mean methylation profile at a number of locations in
another gene, and vice versa. There will probably be fewer ways in which the
methylation levels of these genes covary across the samples than there are
locations at which methylation is measured along the genes; this is because
the methylation level is highly correlated at many locations along a partic-
ular gene. CCA finds the most important components of this covariation
across samples.
CCA seeks to find the vectors a and b, in the p and q dimensional spaces
of variables X = (x1, x2, ..., xp)
′ and Y = (y1, y2, ..., yq)′, respectively, which
maximise the correlation ρ = cor (a′X,b′Y) defined according to equation
1:
(1) ρ =
a′ΣXY b√
a′ΣXXa
√
b′ΣY Y b
,
where
ΣXX = E
[
(X− µX)(X− µX)′
]
and
ΣY Y = E
[
(Y − µY )(Y − µY )′
]
are the covariance matrices of X and Y respectively,
ΣXY = E
[
(X− µX)(Y − µY )′
]
is the cross-covariance matrix of X and Y, and µX and µY are the mean
vectors of X and Y.
Two genes X and Y have corresponding methylation profiles which are
measured for sample / patient k at p and q CpGs (loci) respectively along
these genes. Denoting these measurements by the variables x1, ...xp and
y1, ..., yq for genes X and Y respectively, the DNA methylation profiles for
these genes, for patient k, can be represented by the vectors x(k) and y(k),
which have p and q entries respectively. A measure of DNA methylation
network interaction ρXY (k), of the methylation profiles of genes X and Y
for sample k, can then be defined by analogy with equation 1, according to
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equation 2:
(2) ρXY (k) =
xc(k)T Σˆ
(h)
XY y
c(k)√
xc(k)T Σˆ
(h)
XXx
c(k)
√
yc(k)T Σˆ
(h)
Y Y y
c(k)
,
where Σˆ
(h)
XX , Σˆ
(h)
Y Y and Σˆ
(h)
XY are estimated from healthy rather than cancer
samples in the methylation data set, according to equations 3 - 5,
(3) Σˆ
(h)
XX =
1
nh
∑
k∈healthy
(
x(k)− µˆ(h)X
)(
x(k)− µˆ(h)X
)T
(4) Σˆ
(h)
Y Y =
1
nh
∑
k∈healthy
(
y(k)− µˆ(h)Y
)(
y(k)− µˆ(h)Y
)T
(5) Σˆ
(h)
XY =
1
nh
∑
k∈healthy
(
x(k)− µˆ(h)X
)(
y(k)− µˆ(h)Y
)T
,
where
µˆ
(h)
X =
1
nh
∑
k∈healthy
x(k),
µˆ
(h)
Y =
1
nh
∑
k∈healthy
y(k),
nh is the number of healthy samples in the data set, and x
c(k) and yc(k)
are the mean-centered methylation profiles xc(k) = x(k)− µˆ(h)X and yc(k) =
y(k) − µˆ(h)Y . The DNAm network interaction measure hence evaluates the
extent to which, in an individual tumour sample, the combinations of the
methylation-variables (i.e., loci) in genes X and Y explain each other, or
covary, in the spaces determined by CCA on corresponding healthy sam-
ples; that is, the covariation in tumour sample k between the methylation-
variables in genes X and Y is assessed against typical healthy variability
in these variables. When the DNA methylation network interaction measure
ρXY (k) is large (i.e., close to 1), the corresponding pair of genes explain each
others’ gene-regulatory behaviour (as reflected in their methylation profiles)
well, or have otherwise well-correlated interactive or associative behaviour,
for sample/patient k. Hence, ρXY (k) measures (according to their DNA
methylation profiles) the level of interaction or association between genes X
and Y in tumour sample k, compared to typical interactions between these
genes in healthy tissue.
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Fig 2: The DNA methylation network interaction measure.
A combination of the variation of the healthy methylation profiles in regions (a) and
(b) of gene X explains well / is well-explained by a combination of the variation of
the healthy methylation profiles in regions (c) and (d) of gene Y. The green cancer
sample varies by a large amount about the mean methylation profile and in a typical
way in these regions in both genes. Hence, the green sample corresponds to a high
level of network interaction for this sample, ρXY = 1. The equivalent variations in
the other regions of these genes do not explain each other well, and so the red sample,
which varies by a large amount in these other regions and varies less and in an
atypical way in regions (a) - (d), corresponds to a low level of network interaction,
ρXY = 0.07. Genes X and Y are likely to have different numbers of methylation
measurement locations (i.e., variables X and Y are of different dimension). The
ordering of the measurement locations has no influence on the calculation of ρ,
as long as the ordering is consistent across samples. This diagram was presented
previously by Bartlett, Olhede and Zaikin (2014).
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2.2. Prognostic Network Construction. Our proposed methodology for
inference of network oncomarkers is based on a prognostic interaction net-
work over m genes. This network is represented by the m × m adjacency
matrix A, in which an edge is defined to to be present (i.e., Aij = 1) if
and only if the corresponding pair of genes (nodes) are prognostic according
to the DNA methylation network interaction measure of Section 2.1. Oth-
erwise, we set Aij = 0. We note that i and j are now redefined compared
to the last Section, so that they index genes rather than DNA methylation
locations. This formulation will not be problematic, because all subsequent
analysis is carried out at the level of genes rather than DNA methylation
locations. To identify prognostic edges, we use the Cox proportional hazards
model (Cox, 1972) to calculate a Wald-statistic zij for each of the
(
m
2
)
pairs
of genes in the network. The Wald statistic quantifies the strength of associ-
ation of the DNA methylation network interaction measure ρij for the pair
of genes i and j (i = 1, ...,m and j = 1, ...,m) with patient survival outcome
across patients k (k = 1, ...n). We use a multivariate Cox model, adjusting
these Wald statistics for clinical covariates, fitting this model separately to
each pair of genes (i, j). We adjust in this way in order to detect novel DNA
methylation biomarkers which are independent of known prognostic clinical
features.
The Wald statistic is asymptotically normally distributed with unit vari-
ance (Harrell, 2001), and we can therefore model the distribution of our
observed Wald statistics, zij , as a mixture of Gaussians. We have previously
demonstrated the utility of mixture modelling to a related network infer-
ence problem (Bartlett, 2015), and a similar approach can be applied in this
context. We model the zij as a Gaussian mixture as follows:
zij ∼
{
N (µij , σ2) , if Aij = 1,
N (0, σ2) , if Aij = 0,(6)
where N (µij , σ2) is the normal distribution, and we enforce σ2 = 1 in line
with the asymptotic behaviour of the Wald statistic. We fit this mixture
model to each observed statistic zij , and then infer whether, given zij , it is
more likely that µij = 0, or µij 6= 0, leading to the estimates Aˆij = 0 or
Aˆij = 1 respectively. We fit this model using the empirical Bayes procedure
of Johnstone and Silverman (2004), defining a mixture prior distribution
fprior (µij) over the µij of equation 6:
(7) fprior (µij) = (1− w) δ (µij) + wγ (µij) ,
where w is the mixing parameter between the two components, which can
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also be interpreted as w = E [p (Aij = 1)], and γ (·|a) is the Laplace proba-
bility density function,
γ (µij |a) = a
2
exp (−a |µij |),
where we use the standard value of a = 0.5 (Johnstone and Silverman, 2004).
Taking the mixture components to have Gaussian likelihoods, fN
(·∣∣µij , σ2),
as in equation 6, it follows from equation 7 that the posterior density over
the observed prognostic Wald statistic zij is:
(8)
fposterior (µij |zij) =
(1− w) δ (µij) fN
(
zij
∣∣0, σ2)+ wγ (µij) fN (zij∣∣µij , σ2)
fmarginal (zij)
,
where the marginal density is:
(9) fmarginal (zij) = (1− w)fN
(
zij
∣∣0, σ2)+ wg (zij) ,
where g (µij) is the convolution of the Laplace density with the standard
normal density. If the Laplace distribution in the prior (equation 7) were
replaced with a Gaussian, then the marginal distribution (equation 9) would
be a mixture of Gaussians. However, as noted previously (Johnstone and
Silverman, 2004), this empirical Bayes procedure requires a prior with tails
that are exponential or heavier. Hence, we similarly use the Laplace rather
than Gaussian prior which is a slight model misspecification.
Although a separate model is fitted to each observed Wald statistic zij ,
a common weight wi is used for each gene/node i. We choose to do this,
because estimating wi separately for each gene i allows adaptation to a
heterogenous degree distribution in A, as follows. For a particular gene i, if
the zij are mostly close to zero, then wˆi will be set low, which means that
fewer edges (Aij = 1) will be detected; this hence corresponds to i being a
low-degree node. If for a different gene i the zij are generally further from
zero, then wˆi will be set high, which corresponds more edges being detected;
this hence corresponds to i being a high-degree node.
The estimate wˆi is found as the value which maximises the marginal
likelihood (equation 10) of the observed statistics zij over all the pairwise
comparisons of i with j, j 6= i. This allows the model for each such pairwise
comparison (i, j) to ‘borrow strength’ from all the other comparisons (i, j′),
j′ 6= i, j′ 6= j:
(10) wˆi = arg max
w
∑
j 6=i
log {(1− w)φ (zij) + wg (zij)} .
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As in the original presentation of this methodology (Johnstone and Silver-
man, 2004), we use the posterior median to obtain the estimate µˆij . Then
we make a conservative estimate of A as follows:
Aˆij =1 if µˆij > 0 and µˆji > 0 or µˆij < 0 and µˆji < 0,(11)
Aˆij =0 otherwise.
2.3. Community and Oncomarker Detection. Network nodes can be grouped
together according to their propensity to interact with each other, for exam-
ple groups of friends in a social network, or functional subnetwork modules
in a biological network; this method is referred to as community detection
(Girvan and Newman, 2002; Newman, 2004). We use community detection
to naturally infer groups of genes in our constructed prognostic network.
These groups of genes interact differently in cancer than in healthy tissue,
in a way which is predictive of how advanced the disease is. We term these
groups ‘network community oncomarkers’. Within a network community on-
comarker the genes may interact with each other more (relative to healthy
tissue) the more serious the disease is (as in Figure 6c), or they may interact
with each other less the more serious the disease is, (as in Figure 6a). We
carry out the task of community detection by fitting the degree-corrected
stochastic blockmodel (Holland, Laskey and Leinhardt, 1983; Bickel and
Chen, 2009). We fit this model in an efficient way by regularised spectral
clustering (Qin and Rohe, 2013), calculating the optimum number of com-
munities to divide the network into by the network histogram method (Ol-
hede and Wolfe, 2014). Each community identified in this way represents a
potential network community oncomarker.
For each network community oncomarker, we then calculate a prognostic
score for each patient, by summarising the DNA methylation network inter-
action measure over this group of genes. This prognostic score can be used
as a one-number summary of disease prognosis for that patient according to
that network community oncomarker. The following points are important
when calculating these summaries. Some gene-gene interactions will cor-
respond to an increasingly negative DNA methylation network interaction
measure ρij for worse patient prognosis. On the other hand, some gene-gene
interactions will correspond to an increasingly positive ρij for worse prog-
nosis. This means that care must be taken when summarising the network
interaction measure across the network community oncomarker. Also, for
the same amount of prognostic information conveyed, the magnitude of the
changes in the network interaction measure may not be the same for each
prognostic pairs of genes. To address these points, we combine the ρij across
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the prognostic pairs of genes of the network community after first multi-
plying them by the corresponding fitted Cox proportional hazards model
coefficients θˆij , obtained as described at the start of Section 2.2. Under the
Cox proportional hazards model, the fitted model coefficient θˆij for a pre-
dictor ij gives the log of the hazard ratio (HR) for that predictor in the
model, that is, log (HRij) = θˆij . The hazard ratio is the scale-factor increase
in probability of an event (e.g., death) occurring per unit time, relative to
the baseline hazard (e.g., compared to a control group). Hence, these coeffi-
cients are interpretable in the same way, without scaling issues, across fitted
models. This means that, for patient k, we can combine the DNA methy-
lation network interaction measures over a network community oncomarker
to generate a one-number prognostic score, as follows:
Scorek =
∑
i∈C,j∈C,i<j
Aˆij θˆijρij(k),
where C is the set of nodes in the network community oncomarker, Aˆ is
the inferred adjacency matrix, ρij(k) is the DNA methylation network in-
teraction measure for genes/nodes i and j and patient k, and θˆij is the cor-
responding fitted Cox multivariate proportional-hazards model coefficient.
Network edges/DNA methylation network interaction measures ρij which
increase with poor prognosis (i.e., pairs of genes which interact more as the
disease progresses, coloured green in Figure 6), will correspond to θˆij > 0.
Hence, an increase in such a ρij will increase the prognostic score. Equiv-
alently, network edges/DNA methylation network interaction measures ρij
which decrease with poor prognosis (i.e., pairs of genes which interact less as
the disease progresses, coloured red in Figure 6), will correspond to θˆij < 0.
Hence, a decrease in such a ρij will also increase the prognostic score.
2.4. An equivalent gene-expression interaction measure. To examine fur-
ther the hypothesis that the DNA methylation network interaction mea-
sure is a reflection of co-regulatory or co-regulated gene-expression patterns
(among other genomic effects), we need an equivalent measure of gene-gene
interaction or association in terms of gene expression. We can calculate such
a measure, ρexprXY (k), for gene expression measurements x
expr(k) and yexpr(k)
for the genes X and Y and patient k, as follows (equation 12):
(12) ρexprXY (k) =
(
xexpr(k)− µˆ(h)xexpr
)
σˆ
(h)
xexpr
·
(
yexpr(k)− µˆ(h)yexpr
)
σˆ
(h)
yexpr
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where
µˆ
(h)
xexpr =
1
nh
∑
k∈healthy
xexpr(k) and µˆ
(h)
yexpr =
1
nh
∑
k∈healthy
yexpr(k),
(
σˆ
(h)
xexpr
)2
=
1
nh
∑
k∈healthy
(
xexpr(k)− µˆ(h)xexpr
)2
and (
σˆ
(h)
yexpr
)2
=
1
nh
∑
k∈healthy
(
yexpr(k)− µˆ(h)yexpr
)2
.
The intuition of equation 12 is that when the gene expression measurements
xexpr(k) and yexpr(k) deviate in the same sample from the corresponding
healthy mean expression levels, this measure will be nonzero. When this oc-
curs in the same samples as the DNA methylation network interaction mea-
sure ρXY (k) is also nonzero, we will see a correlation between ρXY (k) and
ρexprXY . These interaction measures for methylation and expression, ρXY (k)
and ρexprXY , are equivalent because they both measure deviation from typical
interactive behaviour in healthy/control samples.
3. Examples. We present an example application of the methodology
proposed in Section 2 to a large publicly available breast cancer invasive
carcinoma (BRCA) dataset downloaded from the Cancer Genome Atlas
(TCGA). We downloaded an initial batch of DNA methylation data for
tumour samples taken from 175 individuals (the training set), together with
clinical data for these samples relating to patient survival outcome, and the
covariates age, disease stage, and residual disease. These training data were
used to detect potential network community oncomarkers. We then down-
loaded DNA methylation data for a further 528 tumour samples (the test
set), together with data for the same clinical features: these independent
samples were used to validate the potential network community oncomark-
ers. We also downloaded corresponding DNA methylation data for healthy
breast tissue samples from 98 individuals to form a reference population of
DNA methylation profiles for this analysis, and we downloaded gene expres-
sion data for 216 of the tumours for which DNA methylation data were also
available. To proceed, we estimated from the training set the healthy pop-
ulation means, covariances and cross-covariances required to calculate the
ρij (i = 1, ...,m and j = 1, ...,m), as well as the corresponding log hazard
ratios θˆij and adjacency matrix Aˆ. Additionally from the training data we
estimated the communities in the adjacency matrix (including the number
of communities) and prognostic score thresholds used to assign patients to
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better and worse prognostic groups. We then used these estimates to verify
the prognostic ability of the methodology in the test set.
We first inferred the binary prognostic adjacency matrix Aˆ for the 175
samples of the BRCA training data set according to the methods set out
in Sections 2.1 - 2.2. DNA methylation data were available for 14829 genes,
and hence the number of nodes/genes m in the inferred adjacency matrix Aˆ
is m = 14829. The presence of an edge in Aˆ, that is, Aˆij = 1, indicates that
the interaction between genes i and j is associated with disease progression.
The edge density of Aˆ is 0.0035, that is, p(Aˆij = 1) = 0.0035. We then
extracted the connected component from this inferred network and carried
out community detection on this connected component as described in Sec-
tion 2.3. This resulted in 33 communities ranging from 116 to 285 nodes
in size. The reduced adjacency matrix relating to these communities [with
m = 5668 and p(Aˆij = 1) = 0.023] is shown in Figure 3. We note that the
stochastic blockmodel, fitted in this way via spectral clustering, does not
provide any uncertainty as to the inferred community assignments: if this
is desired, then mixed-membership stochastic blockmodels are available as
an alternative (Airoldi et al., 2008). In the analysis we present here, uncer-
tainties arising from these inferred community assignments are considered
in the subsequent analyses (Figures 4 and 5 and Tables 1 and 2).
We validated each of the 33 potential network community oncomarkers
in the 528 independent tumour samples of the test/validation set. We note
that these 528 samples were not used in any way to identify the 33 po-
tential network community oncomarkers shown in Figure 3. Hence in this
validation each of these 528 patients were classified individually according
to prognosis without reference to the other validation samples. This means
that comparing these prognostic classifications assigned to the validation
samples is a true test of prognostic ability of the network community onco-
markers. To carry out the validation, we calculated the prognostic score for
the 528 independent/unseen samples of the test set, based on the inferred
prognostic adjacency matrix Aˆ and the fitted Cox multivariate proportional
hazards model coefficients θˆ obtained from the initial 175 samples of the
training set. Using this trained model, we calculated one prognostic score
for each potential network community oncomarker for each of the 528 unseen
test-set samples. We then tested the prognostic score, for each potential net-
work community oncomarker, for significant prediction of patient survival
outcome in these 528 unseen test-set samples. The five potential network
community oncomarkers which validated in this way with the highest level
of significance are outlined in red in Figure 3. The results of univariate
and multivariate Cox regression for these five best network community on-
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(a)
(b)
(c)
(d)
(e)
Fig 3: The inferred prognostic adjacency matrix after community detection.
Entries in the adjacency matrix equal to 1 (representing a network edge) are coloured
blue. Detected communities are outlined in black. The potential network community
oncomarkers which are analysed further in Figures 4 - 7 and Tables 1 - 2 and Tables
S1 - S5 in the supplement are outlined in red, and labelled (a) - (e).
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Fig 4: Network community oncomarkers: Kaplan-Meier plots for the training set.
Comparison of survival curves for the patient groups defined by the prognostic score
for each network community oncomarker. The groups are divided by the median
prognostic score in the 175 samples of the training data set. The hazard ratio (HR)
is displayed with 95% C.I. in brackets, with the corresponding p-value calculated by
univariate Cox regression. (a) - (e) indicate network community oncomarkers 1 -
5, as shown in Figure 3.
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Fig 5: Network community oncomarkers: Kaplan-Meier plots for the test set.
Comparison of survival curves for the patient groups defined by the prognostic score
for each network community oncomarker. The groups are divided by the median
prognostic score in the 175 samples of the training data set. The hazard ratio (HR)
is displayed with 95% C.I. in brackets, with the corresponding p-value calculated by
univariate Cox regression. (a) - (e) indicate network community oncomarkers 1 -
4, as shown in Figure 3.
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comarkers are shown in Figures 4 and 5, and in Tables 1 and 2, for the
training and test sets respectively. Plots equivalent to Figures 4 and 5 for all
33 detected network communities appear in Supplementary Figures S1-S2.
For the multivariate analysis, samples with missing data for any of the clin-
ical covariates were removed, leaving 172 and 396 samples for the training
and test sets respectively. We note that, as would be expected, the level of
significance in the training set (to which the model was fitted, Figure 4 and
Table1), is much higher than in the test set (Figure 5 and Table 2).
Figure 6 shows the five network community oncomarkers which validated
most significantly. Green edges indicate gene-gene interactions which become
stronger with disease progression. Red edges indicate interactions which be-
come weaker with disease progression. Hence, the network community onco-
markers of Figures 6a and 6b can be considered to be functional subnetwork
modules which become less active as the cancer progresses (comprised of
99% and 96% red edges, respectively). On the other hand, Figures 6c and
6d can be considered to be functional subnetwork modules which become
more active as the cancer progresses (both comprised of 99% green edges).
Then the network community oncomarker of Figure 6e contains a mixture of
these effects (comprised of 87% red and 13% green edges). However, each of
these network community oncomarkers represents a functional subnetwork
module which is rewired in a way which is advantageous for the cancer, in
favour of proliferation, and against cell death and immune function. The
genes/nodes of these network community oncomarkers are shown in Tables
S1 - S5 in the supplement; they list many genes related to cell proliferation
(e.g., CDKL1, NKAPL, MAPK6 ), developmental processes (e.g., HOXD10,
HOXB9, HOXC10, HOXA13, HOXC12, HOXD13 ), and immune function
(e.g., VSIG2, IL36B, RBPJ ).
We hypothesise that the DNA methylation network interaction measure is
a reflection of co-regulatory or co-regulated gene-expression patterns, among
other genomic effects. We tested this hypothesis by comparing the DNA
methylation network interaction measure ρXY for a pair of genes XY (equa-
tion 2) with an equivalent measure of interactive behaviour of these genes in
terms of their expression levels, ρexprXY (equation 12). Correlation test p-values
for the comparison between ρXY and ρ
expr
XY appear in Figure 7. It is clear that
in these histograms, there is a concentration of significant p-values close to
zero, indicating a departure from the null hypothesis uniform distribution,
and demonstrating an association between ρXY and ρ
expr
XY for many of the
edges/interactions of each network community oncomarker. However, there
are also many nonsignificant p-values visible in these histograms, indicat-
ing that there are other genomic interactive effects present which cannot be
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HR (95%CI) p n
Prognostic Score 77.1 (10.5-567) <0.001 172
Age 1.79 (0.66-4.84) 0.249 172
Residual Disease 15.4 (4.68-50.9) <0.001 172
Stage 2.85 (0.96-8.46) 0.060 172
(a) Network community oncomarker 1.
HR (95%CI) p n
Prognostic Score 51.3 (8.35-315) <0.001 172
Age 1.42 (0.48-4.23) 0.53 172
Residual Disease 30.4 (5.82-158) <0.001 172
Stage 1.95 (0.68-5.54) 0.212 172
(b) Network community oncomarker 2.
HR (95%CI) p n
Prognostic Score 50.1 (9.77-256) <0.001 172
Age 2.16 (0.81-5.8) 0.125 172
Residual Disease 13.3 (4.54-39.1) <0.001 172
Stage 2.41 (0.81-7.18) 0.114 172
(c) Network community oncomarker 3.
HR (95%CI) p n
Prognostic Score 22.7 (5.52-93.1) <0.001 172
Age 3.49 (1.3-9.42) 0.0135 172
Residual Disease 16.3 (5.24-50.7) <0.001 172
Stage 1.05 (0.38-2.91) 0.928 172
(d) Network community oncomarker 4.
HR (95%CI) p n
Prognostic Score 46.0 (8.17-259) <0.001 172
Age 2.91 (1-8.44) 0.0493 172
Residual Disease 7.04 (2.68-18.5) <0.001 172
Stage 3.74 (1.23-11.4) 0.02 172
(e) Network community oncomarker 5.
Table 1
Network community oncomarkers - training set prognosis.
Multivariate Cox regression was used to test significance of the prognostic scores obtained
from the network community oncomarkers. (a) - (e) indicate network community
oncomarkers 1 - 5, as shown in Figure 3.
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HR (95%CI) p n
Prognostic Score 4.89 (1.65-14.5) 0.00429 396
Age 3.52 (1.46-8.49) 0.00513 396
Residual Disease 12.5 (5.32-29.3) <0.001 396
Stage 1.62 (0.66-4) 0.294 396
(a) Network community oncomarker 1.
HR (95%CI) p n
Prognostic Score 5.07 (1.81-14.1) 0.00195 396
Age 3.67 (1.49-9.03) 0.00458 396
Residual Disease 8.72 (3.78-20.1) <0.001 396
Stage 1.47 (0.6-3.61) 0.406 396
(b) Network community oncomarker 2.
HR (95%CI) p n
Prognostic Score 2.63 (1.01-6.89) 0.0484 396
Age 2.07 (0.86-5) 0.106 396
Residual Disease 11.3 (4.97-25.5) <0.001 396
Stage 2.04 (0.76-5.45) 0.157 396
(c) Network community oncomarker 3.
HR (95%CI) p n
Prognostic Score 4.92 (1.8-13.5) 0.00189 396
Age 1.91 (0.78-4.69) 0.159 396
Residual Disease 17.2 (6.76-43.9) <0.001 396
Stage 0.92 (0.34-2.48) 0.871 396
(d) Network community oncomarker 4.
HR (95%CI) p n
Prognostic Score 2.5 (0.94-6.65) 0.0668 396
Age 2.23 (0.94-5.27) 0.0677 396
Residual Disease 8.17 (3.47-19.3) <0.001 396
Stage 1.59 (0.64-3.95) 0.321 396
(e) Network community oncomarker 5.
Table 2
Network community oncomarkers - test/validation set prognosis.
Multivariate Cox regression was used to test significance of the prognostic scores obtained
from the network community oncomarkers. (a) - (e) indicate network community
oncomarkers 1 - 5, as shown in Figure 3.
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Fig 6: Detected network community oncomarkers.
(a) - (e) indicate network community oncomarkers 1 - 5, as shown in Figure 3.
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Fig 7: Correlation of DNA methylation with gene expression for the network com-
munity oncomarkers.
(a) - (e) indicate network community oncomarkers 1 - 5, as shown in Figure 3.
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explained in terms of gene expression (as assessed by mRNA levels) alone.
Such effects are expected to include the influence of alternatively spliced
products or isoforms (Jones, 2012) and the interaction between noncoding
transcripts and the epigenome (Lai and Shiekhattar, 2014).
4. Discussion. In this paper, we have proposed methodology to de-
tect cancer biomarkers based on the epigenomic pattern DNA methylation.
This methodology builds on a previously proposed measure of pairwise in-
teraction between genes, based on the epigenomic gene-regulatory pattern
DNA methylation (Bartlett, Olhede and Zaikin, 2014). Based on this DNA
methylation network interaction measure, the methodology we describe in
this paper allows inference of prognostic genomic networks, and identifica-
tion of prognostic biomarkers from such networks using community detec-
tion methodology. Community detection has previously proved powerful as
well realistic in a range of fields, including social as well as biological net-
works (Girvan and Newman, 2002). In the context of genomic networks, such
modular groups of genes are known to correspond to specific physiological
functions (Shen-Orr et al., 2002). The modular prognostic biomarkers which
we detect are termed ‘network community oncomarkers’; they are groups of
nodes/genes among which there is a high density of prognostic genomic in-
teractive or associative behaviour. We have demonstrated that within these
communities, the DNA methylation network interaction measure is highly
associated with co-regulatory behaviour linked to gene expression (at the
mRNA level), giving functional relevance to the findings. However, there
are also likely to be a range of genomic interactive effects present which are
measured by the DNA methylation network interaction measure but which
are not reflected in mRNA levels. Our proposed methodology also allows
a one-number prognostic score for a network community oncomarker to be
calculated for each patient/sample: this prognostic score is a measure of
disease progression in that patient.
Our proposed methodology uses mixture modelling to infer network struc-
ture from prognostic association between genes, and draws on practical ap-
proaches to community detection to obtain oncomarkers from this prognostic
network. Mixture modelling has previously been shown to be an effective ap-
proach to the related problem of clustering in networks (Vu et al., 2013).
This suggests that more general methodology could be developed here, in
which network and community inference are both carried out simultaneously
by model fitting. Network inference has also been carried out previously us-
ing multiple node attributes in cell biological data (Katenka et al., 2012),
and those findings could be used as a basis upon which data from other
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genomic sources could be integrated into the methodology proposed here.
Genes also frequently carry out multiple roles in different biological contexts
and hence may be involved in more than one functional subnetwork mod-
ule within a genomic network. Work has been carried out on overlapping
stochastic blockmodels (Latouche et al., 2011), and hence this would be a
natural context in which to develop an application for such methodology.
The field of epigenomics is progressing fast and promises many new in-
sights in the near future into unexplained or undiscovered genomic phe-
nomena, for example relating to the so-called ‘dark matter’ of the genome
(Venters and Pugh, 2013). Epigenomics is also expected to provide new un-
derstanding of the mechanisms of disease progression. The discovery that
some genomic loci gain or lose methylation in ways which may be unique to
cancer suggests that understanding changes in DNA methylation machinery
may be essential to understanding oncogenesis (Xie et al., 2013). The field
of network science is also advancing rapidly. Networks are an efficient way to
represent and analyse large numbers of variables, which is particularly rel-
evant in modern, large-scale genomic studies. Networks of interactions are
a natural way to represent and analyse genomic interactions, associations
and processes. Therefore, the study of genomic and epigenomic networks
promises to be productive over the coming years for the fields of biology,
medicine, and statistics.
5. Datasets. DNA methylation (DNAm) data from breast cancer in-
vasive carcinoma (BRCA) tumour samples, collected via the Illumina In-
finium HumanMethylation450 platform, were downloaded from The Cancer
Genome Atlas (TCGA) project (Hampton, 2006; Bonetta, 2006; Collins and
Barker, 2007) at level 3. These data were preprocessed by first removing
probes with nonunique mappings and which map to SNPs (as identified in
the TCGA level 3 data); probes mapping to sex chromosomes were also re-
moved; in total 98384 probes were removed in this way from all data sets.
After removal of these probes, 270985 probes with known gene annotations
remained. Probes were then removed if they had less than 95% coverage
across samples; probe values were also replaced if they had corresponding
detection p-value greater than 5%, by KNN (k nearest neighbour) imputa-
tion (k = 5). The loci of analysed CpGs were mapped to genes based on
annotation information for the Illumina Infinium platform obtained from
the R / Bioconductor package ‘IlluminaHumanMethylation450k’. The data
were also checked for batch effects by hierarchical clustering and correlation
of the significant principle components with phenotype and batch: no sig-
nificant batch effects (which would warrant further correction) were found.
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We downloaded DNA methylation data for tumour samples from 175 sam-
ples/individuals, from TCGA in July 2013, with clinical data available for
patient survival outcome, and the clinical covariates age, disease stage, and
residual disease. At the same time, we also downloaded corresponding DNA
methylation data for healthy tissue for 98 individuals. These data were used
to detect potential network community oncomarkers. We then downloaded
DNA methylation data for a further 528 tumour samples from TCGA in
September 2014, with data for the same clinical features available. These in-
dependent samples were used to validate the potential network community
oncomarkers. At this time we also downloaded gene expression data from
TCGA at level 3, for 216 of the tumours for which we also obtained DNA
methylation data.
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